Keywords

• (6R,9R)-6-(2,3-difluorophenyl)-9-(triisopropylsilyloxy)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridine
• Rimegepant Impurity80
• 1190363-52-0

Quick Details

• ProName: Rimegepant Impurity80
• CasNo: 1190363-52-0
• Molecular Formula: C25H35F2NOSi
• Appearance: White to off white powder
• Application: experiment research
• DeliveryTime: prompt delivery
• PackAge: Food bags, aluminum foil bags
• Port: Shenzhen/hongkong
• ProductionCapacity: 5000 Gram/Year
• Purity: 99%+ HPLC
• Storage: cool and dry
• Transportation: DHL,EMS,TNT,UPS,EMS,by air,by sea;
• LimitNum: 10 Milligram
• Moisture Content: 0.1%
• Impurity: 0.1%

Superiority

Advantages

• High-Purity Reference Standard：Confirmed by HPLC (≥99.0%), NMR (1H, 13C, 19F), HRMS, and elemental analysis, suitable for Rimegepant impurity analysis and quality control.

• Stability Assurance：Stable for 36 months at -20℃ under light-protected, sealed storage; degradation rate <0.2% in acetonitrile-toluene solution within 6 months.

Details

Rimegepant Impurity80； 1190363-52-0

Product Information

• Product Code：R046080

• English Name：Rimegepant Impurity 80

• English Alias：(6R,9R)-6-(2,3-difluorophenyl)-9-((triisopropylsilyl)oxy)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridine

• CAS No.：1190363-52-0

• Molecular Formula：C??H??F?NOSi

• Molecular Weight：431.63

Applications

• Quality Control Testing：Used for UPLC-MS/MS detection of Impurity 80 in Rimegepant API and formulations, controlling content to meet ICH Q3A standards (single impurity limit ≤0.1%).

• Process Optimization Research：Monitors Impurity 80 formation during Rimegepant synthesis, reducing generation by >50% by adjusting silylation temperature (e.g., -10~0℃) and reaction time.

• Method Validation：Serves as a standard for developing impurity detection methods, verifying UPLC resolution (≥3.0) and LOD (0.01 ng/mL).

Background Description

Rimegepant, a CGRP receptor antagonist, is used for treating migraines. Impurity 80, as a process-related impurity of Rimegepant, may originate from side products of cycloheptapyridine ring fluorination and silylation during synthesis. Its siloxy and difluorophenyl groups may affect drug stability and receptor binding ability. With stricter FDA and EMA requirements for migraine drug impurities, studying Impurity 80 is essential for ensuring drug quality.

Research Status

• Detection Technology：UPLC-MS/MS with C18 column (1.7μm) and 0.1% formic acid-acetonitrile gradient elution achieves separation within 8 minutes, with LOD of 0.005 ng/mL for trace impurity analysis.

• Formation Mechanism：Formed by reaction of (6R,9R)-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-ol with triisopropylchlorosilane under alkaline conditions (e.g., imidazole/DCM system); optimizing catalyst dosage and solvent dryness inhibits side reactions.

• Safety Evaluation：In vitro cytotoxicity shows IC?? of 220.4 μM against HEK293 cells (Rimegepant IC??=8.7 μM), with lower toxicity than the main drug but requiring strict content control. Long-term stability testing is ongoing to monitor degradation under different humidity (40%-75%RH), light (4500lx), and temperature (25℃/60℃) conditions.